Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
J Hematol Oncol
.
2017 Sep 18;10(1):154.
doi: 10.1186/s13045-017-0518-8.
Authors
Francine Foss
1
,
Steven Horwitz
2
,
Barbara Pro
3
,
H Miles Prince
4
,
Lubomir Sokol
5
,
Barbara Balser
6
,
Julie Wolfson
6
,
Bertrand Coiffier
7
Affiliations
1
Yale Cancer Center, 333 Cedar St, TMP 3, PO Box 208028, New Haven, CT, 06520-8028, USA.
[email protected]
.
2
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
3
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
4
Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.
5
Moffitt Cancer Center, Tampa, FL, USA.
6
Veristat, LLC, Southborough, MA, USA.
7
Hospices Civils de Lyon, Lyon, France.
PMID:
28923081
PMCID:
PMC5603163
DOI:
10.1186/s13045-017-0518-8
No abstract available
Publication types
Published Erratum
Grants and funding
UL1 TR001863/TR/NCATS NIH HHS/United States